Diabetes care · 2019
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
СтатьяОбзорПоддержка NIH: внешняя программаConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Danne Thomas, Garg Satish, Peters Anne L, Buse John B, Mathieu Chantal, Pettus Jeremy H, Alexander Charles M, Battelino Tadej, Ampudia-Blasco F Javier, Bode Bruce W, Cariou Bertrand, Close Kelly L, Dandona Paresh, Dutta Sanjoy, Ferrannini Ele, Fourlanos Spiros, Grunberger George, Heller Simon R, Henry Robert R, Kurian Martin J, Kushner Jake A, Oron Tal, Parkin Christopher G, Pieber Thomas R, Rodbard Helena W, Schatz Desmond, Skyler Jay S, Tamborlane William V, Yokote Koutaro, Phillip Moshe
Аннотация
Sodium-glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.